2-Chlorodeoxyadenosine (cladribine) induces apoptosis in human monocyte-derived dendritic cells

Clinical and Experimental Immunology

Volumn 173, Issue 2, 2013, Pages 288-297

  Singh, V ^a,b   Prajeeth, C K ^a   Gudi, V ^a   Benardais K ^a,b   Voss, E V ^a   Stangel, M ^a,b  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b CENTER FOR SYSTEMS NEUROSCIENCE   (Germany)

Author keywords

caspases; cladribine; DNA fragmentation; mitochondrial potential; phosphatidylserine

Indexed keywords

CASPASE 3; CASPASE 9; CD14 ANTIGEN; CLADRIBINE; PROTEIN P53; TUMOR NECROSIS FACTOR ALPHA;

APOPTOSIS; ARTICLE; CELL DEATH; CELL MATURATION; CONTROLLED STUDY; DENDRITIC CELL; DNA FRAGMENTATION; DOWN REGULATION; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IN VITRO STUDY; MITOCHONDRIAL MEMBRANE POTENTIAL; MONOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; UPREGULATION;

CASPASES; CLADRIBINE; DNA FRAGMENTATION; MITOCHONDRIAL POTENTIAL; PHOSPHATIDYLSERINE;

APOPTOSIS; CASPASE 3; CASPASE 9; CELL DIFFERENTIATION; CELLS, CULTURED; CLADRIBINE; DENDRITIC CELLS; DNA DAMAGE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEUKEMIA, HAIRY CELL; MEMBRANE POTENTIAL, MITOCHONDRIAL; MONOCYTES; MULTIPLE SCLEROSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84880031119     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12109     Document Type: Article

References (49)

1. Dzopalic T, Rajkovic I, Dragicevic A, Colic M. The response of human dendritic cells to co-ligation of pattern-recognition receptors. Immunol Res 2012; 52:20-33.
2. Cravens PD, Lipsky PE. Dendritic cells, chemokine receptors and autoimmune inflammatory diseases. Immunol Cell Biol 2002; 80:497-505.
3. Korn T. Pathophysiology of multiple sclerosis. J Neurol 2008; 255 (Suppl. 6):2-6.
4. Martino G, Furlan R, Brambilla E etal. Cytokines and immunity in multiple sclerosis: the dual signal hypothesis. J Neuroimmunol 2000; 109:3-9.
5. Karni A, Abraham M, Monsonego A etal. Innate immunity in multiple sclerosis: myeloid dendritic cells in secondary progressive multiple sclerosis are activated and drive a proinflammatory immune response. J Immunol 2006; 177:4196-4202.
6. Longhini AL, von Glehn F, Brandao CO etal. Plasmacytoid dendritic cells are increased in cerebrospinal fluid of untreated patients during multiple sclerosis relapse. J Neuroinflammation 2011; 8:1-4.
7. Shortman K, Naik SH. Steady-state and inflammatory dendritic-cell development. Nat Rev Immunol 2007; 7:19-30.
8. Osugi Y, Vuckovic S, Hart DN. Myeloid blood CD11c(+) dendritic cells and monocyte-derived dendritic cells differ in their ability to stimulate T lymphocytes. Blood 2002; 100:2858-2866.
9. Huang YM, Xiao BG, Ozenci V etal. Multiple sclerosis is associated with high levels of circulating dendritic cells secreting pro-inflammatory cytokines. J Neuroimmunol 1999; 99:82-90.
10. Bartosik-Psujek H, Tabarkiewicz J, Pocinska K, Radej S, Stelmasiak Z, Rolinski J. Immunomodulatory effects of IFN-beta and lovastatin on immunophenotype of monocyte-derived dendritic cells in multiple sclerosis. Arch Immunol Ther Exp (Warsz) 2010; 58:313-319.
11. Vieira PL, Heystek HC, Wormmeester J, Wierenga EA, Kapsenberg ML. Glatiramer acetate (copolymer-1, copaxone) promotes Th2 cell development and increased IL-10 production through modulation of dendritic cells. J Immunol 2003; 170:4483-4488.
12. del Pilar Martin M, Cravens PD, Winger R etal. Decrease in the numbers of dendritic cells and CD4+ T cells in cerebral perivascular spaces due to natalizumab. Arch Neurol 2008; 65:1596-1603.
13. Yen JH, Ganea D. Interferon beta induces mature dendritic cell apoptosis through caspase-11/caspase-3 activation. Blood 2009; 114:1344-1354.
14. Giovannoni G, Comi G, Cook S etal. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med 2010; 362:416-426.
15. Giovannoni G, Cook S, Rammohan K etal. Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis. Lancet Neurol 2011; 10:329-337.
16. Carson DA, Wasson DB, Taetle R, Yu A. Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes. Blood 1983; 62:737-743.
17. Carrera CJ, Terai C, Lotz M etal. Potent toxicity of 2-chlorodeoxyadenosine toward human monocytes in vitro and in vivo. A novel approach to immunosuppressive therapy. J Clin Invest 1990; 86:1480-1488.
18. Beutler E. Cladribine (2-chlorodeoxyadenosine). Lancet 1992; 340:952-956.
19. Marzo I, Perez-Galan P, Giraldo P, Rubio-Felix D, Anel A, Naval J. Cladribine induces apoptosis in human leukaemia cells by caspase-dependent and -independent pathways acting on mitochondria. Biochem J 2001; 359:537-546.
20. Singh V, Voss EV, Benardais K, Stangel M. Effects of 2-chlorodeoxyadenosine (Cladribine) on primary rat microglia. J Neuroimmune Pharmacol 2012; 7:939-950.
21. Bartosik-Psujek H, Belniak E, Mitosek-Szewczyk K, Dobosz B, Stelmasiak Z. Interleukin-8 and RANTES levels in patients with relapsing-remitting multiple sclerosis (RR-MS) treated with cladribine. Acta Neurol Scand 2004; 109:390-392.
22. Wiesemann E, Sonmez D, Heidenreich F, Windhagen A. Interferon-beta increases the stimulatory capacity of monocyte-derived dendritic cells to induce IL-13, IL-5 and IL-10 in autologous T-cells. J Neuroimmunol 2002; 123:160-169.
23. Koopman G, Reutelingsperger CP, Kuijten GA, Keehnen RM, Pals ST, van Oers MH. Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood 1994; 84:1415-1420.
24. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 1991; 139:271-279.
25. Gogolak P, Rethi B, Szatmari I etal. Differentiation of CD1a- and CD1a+ monocyte-derived dendritic cells is biased by lipid environment and PPARgamma. Blood 2007; 109:643-652.
26. Miller E. Apoptosis measurement by annexin V staining. Methods Mol Med 2004; 88:191-202.
27. Jongbloed SL, Kassianos AJ, McDonald KJ etal. Human CD141+ (BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens. J Exp Med 2010; 207:1247-1260.
28. Genini D, Adachi S, Chao Q etal. Deoxyadenosine analogs induce programmed cell death in chronic lymphocytic leukemia cells by damaging the DNA and by directly affecting the mitochondria. Blood 2000; 96:3537-3543.
29. Vaux DL. Apoptogenic factors released from mitochondria. Biochim Biophys Acta 2011; 1813:546-550.
30. Shi Y. Caspase activation: revisiting the induced proximity model. Cell 2004; 117:855-858.
31. Reinhardt HC, Schumacher B. The p53 network: cellular and systemic DNA damage responses in aging and cancer. Trends Genet 2012; 28:128-136.
32. Nagata S. Apoptotic DNA fragmentation. Exp Cell Res 2000; 256:12-18.
33. Qiao L, Koutsos M, Tsai LL etal. Staurosporine inhibits the proliferation, alters the cell cycle distribution and induces apoptosis in HT-29 human colon adenocarcinoma cells. Cancer Lett 1996; 107:83-89.
34. Riccardi C, Nicoletti I. Analysis of apoptosis by propidium iodide staining and flow cytometry. Nat Protoc 2006; 1:1458-1461.
35. Bontemps F, Meier C, Delacauw A, Balzarini J, Galmarini C, van den Neste E. Study of the efficacy of a pronucleotide of 2-chloro-2′-deoxyadenosine in deoxycytidine kinase-deficient lymphoma cells. Nucleosides Nucleotides Nucleic Acids 2006; 25:997-1000.
36. Downing I, MacDonald SL, Atkinson AP, Turner ML, Kilpatrick DC. Drug modification of LPS-stimulated human monocyte-derived dendritic cells. Br J Biomed Sci 2012; 69:126-133.
37. Robak T, Wierzbowska A, Robak E. Recent clinical trials of cladribine in hematological malignancies and autoimmune disorders. Rev Recent Clin Trials 2006; 1:15-34.
38. Leist TP, Vermersch P. The potential role for cladribine in the treatment of multiple sclerosis: clinical experience and development of an oral tablet formulation. Curr Med Res Opin 2007; 23:2667-2676.
39. Albertioni F, Lindemalm S, Reichelova V etal. Pharmacokinetics of cladribine in plasma and its 5′-monophosphate and 5′-triphosphate in leukemic cells of patients with chronic lymphocytic leukemia. Clin Cancer Res 1998; 4:653-658.
40. Liliemark J. The clinical pharmacokinetics of cladribine. Clin Pharmacokinet 1997; 32:120-131.
41. Castedo M, Hirsch T, Susin SA etal. Sequential acquisition of mitochondrial and plasma membrane alterations during early lymphocyte apoptosis. J Immunol 1996; 157:512-521.
42. Mansson E, Spasokoukotskaja T, Sallstrom J, Eriksson S, Albertioni F. Molecular and biochemical mechanisms of fludarabine and cladribine resistance in a human promyelocytic cell line. Cancer Res 1999; 59:5956-5963.
43. Van den Neste E, Cardoen S, Offner F, Bontemps F. Old and new insights into the mechanisms of action of two nucleoside analogs active in lymphoid malignancies: fludarabine and cladribine (review). Int J Oncol 2005; 27:1113-1124.
44. Nicolo C, Tomassini B, Rippo MR, Testi R. UVB-induced apoptosis of human dendritic cells: contribution by caspase-dependent and caspase-independent pathways. Blood 2001; 97:1803-1808.
45. O'Gorman DM, Cotter TG. Molecular signals in anti-apoptotic survival pathways. Leukemia 2001; 15:21-34.
46. Vogelstein B, Kinzler KW. p53 function and dysfunction. Cell 1992; 70:523-526.
47. Borner MM, Joncourt F, Hotz MA. Similarity of apoptosis induction by 2-chlorodeoxyadenosine and cisplatin in human mononuclear blood cells. Br J Cancer 1997; 76:1448-1454.
48. Szondy Z. The 2-chlorodeoxyadenosine-induced cell death signalling pathway in human thymocytes is different from that induced by 2-chloroadenosine. Biochem J 1995; 311 (Pt 2):585-588.
49. Serafini B, Rosicarelli B, Magliozzi R etal. Dendritic cells in multiple sclerosis lesions: maturation stage, myelin uptake, and interaction with proliferating T cells. J Neuropathol Exp Neurol 2006; 65:124-141.